Frontage Laboratories, a Baird Capital Partners Asia Portfolio Company, Continues to Grow its China Business and Add Talent
Malvern, PA and Shanghai, China, February 23, 2009
Frontage Laboratories Inc. (“Frontage”), a leading high quality provider of bioanalytical, pre-clinical, clinical and drug development services to global pharmaceutical companies, is pleased to announce it has expanded its research and development agreement with Beijing Second Pharmaceuticals, the ethical drug division of Beijing Pharmaceutical Group (“Beijing Pharma”), to accelerate Beijing Pharma’s entrance into the international generic drug market. In addition, Frontage recently hired Len Stigliano as Chief Financial Officer and Derek (Yuanchao) Zhang, Ph.D. as Vice President of Regulatory Affairs and Clinical Pharmacology. These investments further strengthen Frontage’s market leadership as a U.S. – China contract research organization.
Read the full article